What Causes Low Libido with Fibroids?

What Causes Low Libido with Fibroids?

Fibroids lower libido primarily through estrogen dominance — the same hormonal environment that feeds fibroid growth also suppresses free testosterone and disrupts the hypothalamic-pituitary-gonadal (HPG) axis. The main caveat: pain and heavy bleeding compound this significantly, so the mechanism is rarely single-threaded. Women who manage blood loss and inflammation often see partial libido recovery even before fibroids shrink.

---

How Fibroids Create an Estrogen-Dominant Hormonal Environment

Uterine fibroids are estrogen- and progesterone-sensitive tumors. They express estrogen receptor-α at concentrations roughly two to three times higher than surrounding myometrium, and they upregulate aromatase — the enzyme that converts androgens into estrogens locally (Bulun et al., Journal of Clinical Endocrinology & Metabolism 2010; PMID: 20610596). The result is a self-reinforcing loop: fibroids amplify local estrogen signaling, which in turn drives further fibroid growth and suppresses progesterone sensitivity.

Estrogen dominance depresses libido through at least two pathways. First, elevated estrogen increases sex hormone-binding globulin (SHBG), which binds free testosterone and renders it biologically inactive. Even women with technically normal total testosterone can have dramatically reduced free testosterone when SHBG is elevated. Second, progesterone — which normally opposes estrogen and has a well-documented pro-libido effect at the central nervous system level — is relatively deficient in an estrogen-dominant state (Cappelletti & Wallen, Hormones and Behavior 2016; PMID: 26589379). The combined effect is a hormonal milieu that is physiologically hostile to sexual desire.

---

Low Ferritin and the Energy Debt That Kills Desire

Fibroids are the leading cause of heavy menstrual bleeding in reproductive-age women, and heavy bleeding depletes iron stores faster than diet can replace them. Ferritin below 30 ng/mL — a range many labs still report as "normal" — is independently associated with fatigue, impaired cognitive function, and reduced physical capacity (Jimenez et al., Nutrients 2023; PMID: 36679977). Libido competes poorly against exhaustion.

The connection between low ferritin and libido in women is often underappreciated in clinical settings. Iron is a required cofactor for dopamine synthesis — specifically for tyrosine hydroxylase, the rate-limiting enzyme in the dopamine pathway. Dopamine is central to motivational salience and sexual desire. When ferritin is depleted, dopamine synthesis slows, and desire fades along with energy and motivation. Testing ferritin (not just hemoglobin) is therefore a non-negotiable biomarker in any fibroid-related libido workup.

Biomarkers to test:

---

How Chronic Inflammation and Stress Suppress the HPG Axis

Fibroids are not passive masses — they secrete pro-inflammatory cytokines including IL-6, IL-8, and TNF-α, creating a low-grade systemic inflammatory state (Ciebiera et al., BioMed Research International 2017; PMID: 28656149). Inflammation at this level activates the HPA axis (hypothalamic-pituitary-adrenal axis), elevating cortisol. Chronically elevated cortisol then directly inhibits GnRH pulsatility — the upstream signal that triggers LH and FSH release, which in turn drive testosterone and progesterone production.

Many women with fibroids also carry a substantial psychological stress burden: worry about fertility, pain management, and the decisions around surgery. Perceived chronic stress elevates cortisol independently of the fibroid's cytokine output. The two signals stack. The net effect on the HPG axis is a measurable reduction in LH pulse frequency and amplitude, which translates to lower gonadal hormone output and, predictably, reduced libido (Whirledge & Cidlowski, Endocrinology 2010; PMID: 20702573).

Managing the stress-cortisol-HPG loop is therefore a legitimate and evidence-based target — not a dismissive "just relax" recommendation. Adaptogens that modulate HPA axis reactivity, adequate sleep, and reducing the inflammatory burden of the fibroids themselves are all mechanistically coherent strategies.

---

The Gut-Hormone Connection: How Digestive Health Affects Estrogen Clearance

An often-overlooked driver of estrogen dominance in fibroid patients is impaired estrogen detoxification through the gut. The estrobolome — the collection of gut bacteria that produce β-glucuronidase — determines how efficiently the liver's conjugated estrogens are excreted versus deconjugated and reabsorbed. When the estrobolome is dysbiotic, β-glucuronidase activity rises, estrogen recirculates, and systemic estrogen load increases (Kwa et al., Journal of the National Cancer Institute 2016; PMID: 27107051).

Digestive symptoms including bloating and irregular bowel habits are common in fibroid patients — partly from uterine pressure on the colon and partly from the inflammatory cytokine environment. This bidirectional relationship means gut health isn't tangential to fibido in fibroids: it's mechanistically central. Probiotic capsules vs fermented foods for gut colonization is a meaningful conversation for fibroid patients specifically because improving estrobolome composition is a lever for reducing estrogen recirculation.

Dietary fiber (25–38 g/day) accelerates fecal estrogen excretion. Calcium-d-glucarate supplementation has been investigated as a β-glucuronidase inhibitor, though high-quality RCT data in fibroid populations remain limited. Liver phase I and II detoxification support — particularly glucuronidation and sulfation pathways — is a rational complementary target.

---

Pain, Dyspareunia, and the Learned Avoidance Loop

Submucosal and intramural fibroids frequently cause dyspareunia (painful intercourse), particularly with deep penetration. The mechanism is mechanical — uterine enlargement changes the vaginal axis and increases pressure sensitivity — but the psychological consequence is a conditioned avoidance response that persists even on days without pain (Ferrero et al., Human Reproduction 2006; PMID: 16581516). The brain begins to associate sexual activity with the anticipation of pain, which is one of the most effective libido suppressants known.

This is distinct from the hormonal suppression discussed above and requires its own intervention track: pelvic floor physical therapy, positional modifications, and in some cases short-term pain modulation strategies. Identifying whether a patient's low libido is primarily hormonal/nutritional or primarily pain-mediated — or both — is essential for directing the right support.

---

The Mood-Libido Link with Fibroids

Depression and anxiety symptoms are roughly twice as prevalent in women with symptomatic fibroids compared to controls, driven by sleep disruption from nocturia and cramping, chronic pain, and the psychosocial burden of the condition. Depression is one of the strongest independent predictors of low libido across all populations, and what causes low mood with fibroids overlaps substantially with the hormonal and inflammatory mechanisms discussed above. Low progesterone reduces allopregnanolone — a neurosteroid with anxiolytic and antidepressant properties — creating a biochemical substrate for mood disturbance that directly feeds into desire suppression.

Dopamine depletion from low ferritin, elevated cortisol from HPA activation, and progesterone deficiency all converge on mood. In clinical practice, treating mood symptoms and libido symptoms as separate problems misses their shared root causes.

---

Biomarker-to-Protocol Pathway

For a clinician or a well-informed patient working through fibroid-related low libido, the logical sequence is:

1. Rule out iron-deficiency anemia and low ferritin. Test ferritin, CBC, transferrin saturation. Optimize ferritin to ≥50 ng/mL before attributing libido loss to hormonal causes alone.
2. Assess the hormonal environment. Free testosterone, SHBG, estradiol, and mid-luteal progesterone provide the most actionable snapshot. Do not rely on total testosterone.
3. Evaluate inflammatory load. High-sensitivity CRP and, where available, IL-6 give a window into how much cytokine burden the fibroids are generating.
4. Assess cortisol rhythm. A 4-point salivary cortisol or DUTCH test reveals whether HPA dysregulation is contributing to HPG suppression.
5. Evaluate gut function. Stool testing for β-glucuronidase activity and gut microbiome diversity is available through functional labs and can identify estrobolome dysbiosis.
6. Address pain separately. Pelvic floor assessment should run in parallel with the metabolic workup, not sequentially.

For a broader understanding of how hormonal, nutritional, and stress drivers interact in reduced desire, the low libido: hormonal, nutritional, and stress drivers overview is a useful companion resource.

---

What This Means for Your Formula

A fibroid-related libido protocol that only addresses one driver is unlikely to succeed. The estrogen dominance, iron depletion, HPA dysregulation, and gut-estrobolome dysfunction all require targeted support. Ones builds personalized capsule formulas by analyzing lab results and health history, which means the formula can be calibrated to the specific biomarker pattern — not a generic women's health stack.

Three ingredient categories are particularly relevant to the fibroid-libido axis:

• Ashwagandha (KSM-66, 600 mg/day): A double-blind RCT of 57 women found that KSM-66 at 600 mg daily significantly improved sexual function scores including desire, arousal, and satisfaction compared to placebo, alongside measurable reductions in cortisol (Dongre et al., BioMed Research International 2015; PMID: 26609282). In the fibroid context, cortisol reduction takes direct pressure off the HPA-HPG axis suppression loop.

• Omega-3 (EPA + DHA, combined ≥2g/day): Long-chain omega-3s reduce prostaglandin E2 and leukotriene B4 synthesis, blunting the inflammatory cytokine environment that fibroids generate. Reducing systemic CRP supports HPA axis normalization. Ones sources pharmaceutical-grade omega-3 dosed in the range supported by anti-inflammatory trials. For more on low omega-3 symptoms and testing, the clinical thresholds for EPA/DHA are worth reviewing.

• Liver Support (Ones proprietary blend): The Ones Liver Support blend targets hepatic phase I/II detoxification pathways, directly supporting the glucuronidation and sulfation steps that eliminate conjugated estrogens. When the liver clears estrogens efficiently and the gut doesn't reabsorb them, the estrogen dominance that drives both fibroid growth and libido suppression is reduced at its source.

The formula is matched to a 6- or 9-capsule daily plan by the Ones AI based on the severity and pattern of a user's findings — not self-selected from a menu.

---

Key Takeaways

• Fibroids create estrogen dominance by upregulating aromatase and estrogen receptor expression, which elevates SHBG and depresses free testosterone — the most direct hormonal driver of low libido.
• Heavy menstrual bleeding depletes ferritin, and ferritin below 50 ng/mL impairs dopamine synthesis — the neurotransmitter most central to sexual desire and motivation.
• Fibroid-derived cytokines (IL-6, TNF-α) activate the HPA axis and raise cortisol, which inhibits GnRH pulsatility and reduces downstream testosterone and progesterone output.
• The estrobolome — gut bacteria that regulate estrogen reabsorption — is a modifiable lever for reducing systemic estrogen burden; dysbiosis makes estrogen dominance worse.
• Dyspareunia from uterine enlargement creates a learned avoidance response that suppresses libido independently of hormonal drivers; pelvic floor assessment is a distinct but essential workup step.
• A complete biomarker panel (ferritin, free testosterone, SHBG, estradiol, progesterone, CRP, cortisol rhythm) is required to distinguish the dominant driver and direct the right protocol for each individual.

---

This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any supplement protocol or making changes to your treatment plan.